The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Behavioral Symptoms

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Behavioral Symptoms


Psychiatry related information on Behavioral Symptoms


High impact information on Behavioral Symptoms

  • Our results indicate that the behavioral symptoms of neuropathic pain states can be treated successfully, and that partial to complete reversal of associated morphological and neurochemical changes is achievable with artemin [11].
  • Alzheimer disease causes both cognitive and functional impairments that predispose the patient to behavioral symptoms, destroy intellectual capacity and personality, erase the ability to communicate one's wishes for care, and lead to life-threatening consequences [12].
  • MAIN OUTCOME MEASURES: Mood and behavioral symptoms were monitored with daily self-ratings, and lumbar punctures were performed during both hypogonadal (placebo) and testosterone-replaced conditions for CSF levels of steroids and monoamine metabolites [13].
  • The challenge is to elucidate the brain mechanisms of MDD behavioral symptoms, chiefly those of anhedonia [14].
  • No significant correlation was observed between changes in CSF and plasma MT, CSF MHPG, and behavioral symptoms [15].

Chemical compound and disease context of Behavioral Symptoms

  • Risperidone was superior to placebo in reducing repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02) [16].
  • Both haloperidol and lithium carbonate were found to be significantly superior to placebo in decreasing behavioral symptoms [17].
  • RESULTS: Eleven (65%) of the 17 patients who completed both test days showed a significant global worsening of behavioral symptoms with short-term tryptophan depletion, but none of the 17 patients showed any significant change in clinical status from baseline after sham depletion (P = .001) [18].
  • In this double-blind, placebo-controlled study the administration of haloperidol resulted in significant decreases in behavioral symptoms and in general clinical improvement in 40 autistic children ages 2.33 to 6.92 years [19].
  • The authors discuss the sensory, psychological, and behavioral symptoms of phencyclidine intoxication [20].

Biological context of Behavioral Symptoms


Anatomical context of Behavioral Symptoms


Gene context of Behavioral Symptoms

  • We observed a 62% decrease in brainstem TPH activity (p = 0.009) in 4-week-old R6/2 mice, well before the onset of behavioral symptoms [28].
  • This increase in CRF neuronal activity is also believed to mediate certain of the behavioral symptoms of depression involving sleep and appetite disturbances, reduced libido, and psychomotor changes [29].
  • Although phencyclidine is known as a N-methyl d-aspartate receptor antagonist (NMDA-R), the molecular events underlying the behavioral symptoms remain largely unknown [30].
  • Effect of the selective 5-HT3 receptor antagonists ICS 205-930 and MDL 72222 on 5-HTP-induced head shaking and behavioral symptoms induced by 5-methoxy-N,N,dimethyltryptamine in rats: comparison with some other 5-HT receptor antagonists [31].
  • Children with a genetic vulnerability to ADHD may have hidden cognitive deficits in the absence of manifest behavioral symptoms [32].

Analytical, diagnostic and therapeutic context of Behavioral Symptoms


  1. HPRT-APRT-deficient mice are not a model for lesch-nyhan syndrome. Engle, S.J., Womer, D.E., Davies, P.M., Boivin, G., Sahota, A., Simmonds, H.A., Stambrook, P.J., Tischfield, J.A. Hum. Mol. Genet. (1996) [Pubmed]
  2. Allopregnanolone levels and symptom improvement in severe premenstrual syndrome. Freeman, E.W., Frye, C.A., Rickels, K., Martin, P.A., Smith, S.S. Journal of clinical psychopharmacology. (2002) [Pubmed]
  3. Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Tillerson, J.L., Caudle, W.M., Reverón, M.E., Miller, G.W. Exp. Neurol. (2002) [Pubmed]
  4. Psychologic and psychoeducational consequences of thyroxine therapy for juvenile acquired hypothyroidism. Rovet, J.F., Daneman, D., Bailey, J.D. J. Pediatr. (1993) [Pubmed]
  5. Pressure-induced striatal dopamine release correlates hyperlocomotor activity in rats exposed to high pressure. Abraini, J.H., Rostain, J.C. J. Appl. Physiol. (1991) [Pubmed]
  6. Clonidine treatment of Gilles de la Tourette's syndrome. Leckman, J.F., Hardin, M.T., Riddle, M.A., Stevenson, J., Ort, S.I., Cohen, D.J. Arch. Gen. Psychiatry (1991) [Pubmed]
  7. Association of plasma homovanillic acid with behavioral symptoms in patients diagnosed with dementia: a preliminary report. Sweet, R.A., Pollock, B.G., Mulsant, B.H., Rosen, J., Lo, K.H., Yao, J.K., Henteleff, R.A., Mazumdar, S. Biol. Psychiatry (1997) [Pubmed]
  8. Effects of donepezil on emotional/behavioral symptoms in Alzheimer's disease patients. Weiner, M.F., Martin-Cook, K., Foster, B.M., Saine, K., Fontaine, C.S., Svetlik, D.A. The Journal of clinical psychiatry. (2000) [Pubmed]
  9. The role of central oxytocin in obsessive compulsive disorder and related normal behavior. Leckman, J.F., Goodman, W.K., North, W.G., Chappell, P.B., Price, L.H., Pauls, D.L., Anderson, G.M., Riddle, M.A., McDougle, C.J., Barr, L.C. Psychoneuroendocrinology (1994) [Pubmed]
  10. Striatal neurochemical changes in transgenic models of Huntington's disease. Ariano, M.A., Aronin, N., Difiglia, M., Tagle, D.A., Sibley, D.R., Leavitt, B.R., Hayden, M.R., Levine, M.S. J. Neurosci. Res. (2002) [Pubmed]
  11. Multiple actions of systemic artemin in experimental neuropathy. Gardell, L.R., Wang, R., Ehrenfels, C., Ossipov, M.H., Rossomando, A.J., Miller, S., Buckley, C., Cai, A.K., Tse, A., Foley, S.F., Gong, B., Walus, L., Carmillo, P., Worley, D., Huang, C., Engber, T., Pepinsky, B., Cate, R.L., Vanderah, T.W., Lai, J., Sah, D.W., Porreca, F. Nat. Med. (2003) [Pubmed]
  12. Alzheimer Disease: "It's okay, Mama, if you want to go, it's okay". Hurley, A.C., Volicer, L. JAMA (2002) [Pubmed]
  13. Monoamines and neurosteroids in sexual function during induced hypogonadism in healthy men. Bloch, M., Rubinow, D.R., Berlin, K., Kevala, K.R., Kim, H.Y., Schmidt, P.J. Arch. Gen. Psychiatry (2006) [Pubmed]
  14. Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Tremblay, L.K., Naranjo, C.A., Graham, S.J., Herrmann, N., Mayberg, H.S., Hevenor, S., Busto, U.E. Arch. Gen. Psychiatry (2005) [Pubmed]
  15. Cerebrospinal fluid and behavioral changes after methyltestosterone administration: preliminary findings. Daly, R.C., Su, T.P., Schmidt, P.J., Pickar, D., Murphy, D.L., Rubinow, D.R. Arch. Gen. Psychiatry (2001) [Pubmed]
  16. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. McDougle, C.J., Holmes, J.P., Carlson, D.C., Pelton, G.H., Cohen, D.J., Price, L.H. Arch. Gen. Psychiatry (1998) [Pubmed]
  17. Behavioral efficacy of haloperidol and lithium carbonate. A comparison in hospitalized aggressive children with conduct disorder. Campbell, M., Small, A.M., Green, W.H., Jennings, S.J., Perry, R., Bennett, W.G., Anderson, L. Arch. Gen. Psychiatry (1984) [Pubmed]
  18. Effects of tryptophan depletion in drug-free adults with autistic disorder. McDougle, C.J., Naylor, S.T., Cohen, D.J., Aghajanian, G.K., Heninger, G.R., Price, L.H. Arch. Gen. Psychiatry (1996) [Pubmed]
  19. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Anderson, L.T., Campbell, M., Grega, D.M., Perry, R., Small, A.M., Green, W.H. The American journal of psychiatry. (1984) [Pubmed]
  20. Clinical pharmacology of phencyclidine toxicity. Showalter, C.V., Thornton, W.E. The American journal of psychiatry. (1977) [Pubmed]
  21. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Fornai, F., Schlüter, O.M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C.L., Pontarelli, F., Battaglia, G., Pellegrini, A., Nicoletti, F., Ruggieri, S., Paparelli, A., Südhof, T.C. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  22. Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. Scarmeas, N., Brandt, J., Albert, M., Devanand, D.P., Marder, K., Bell, K., Ciappa, A., Tycko, B., Stern, Y. Neurology (2002) [Pubmed]
  23. Distribution of inclusions in neuronal nuclei and dystrophic neurites in Huntington disease brain. Maat-Schieman, M.L., Dorsman, J.C., Smoor, M.A., Siesling, S., Van Duinen, S.G., Verschuuren, J.J., den Dunnen, J.T., Van Ommen, G.J., Roos, R.A. J. Neuropathol. Exp. Neurol. (1999) [Pubmed]
  24. Functional investigations into the role of dopamine and serotonin in partial bilateral striatal 6-hydroxydopamine lesioned rats. Scholtissen, B., Deumens, R., Leentjens, A.F., Schmitz, C., Blokland, A., Steinbusch, H.W., Prickaerts, J. Pharmacol. Biochem. Behav. (2006) [Pubmed]
  25. Buspirone, Parkinson's disease, and the locus ceruleus. Ludwig, C.L., Weinberger, D.R., Bruno, G., Gillespie, M., Bakker, K., LeWitt, P.A., Chase, T.N. Clinical neuropharmacology. (1986) [Pubmed]
  26. Development of the paramedian lobule of the cerebellum in wild-type and tottering mice. Isaacs, K.R., Abbott, L.C. Dev. Neurosci. (1992) [Pubmed]
  27. The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Grossberg, G.T. International psychogeriatrics / IPA. (2002) [Pubmed]
  28. Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease. Yohrling IV, G.J., Jiang, G.C., DeJohn, M.M., Robertson, D.J., Vrana, K.E., Cha, J.H. J. Neurochem. (2002) [Pubmed]
  29. The role of corticotropin-releasing factor in depression and anxiety disorders. Arborelius, L., Owens, M.J., Plotsky, P.M., Nemeroff, C.B. J. Endocrinol. (1999) [Pubmed]
  30. Phencyclidine-induced changes in rat cortical gene expression identified by microarray analysis: implications for schizophrenia. Kaiser, S., Foltz, L.A., George, C.A., Kirkwood, S.C., Bemis, K.G., Lin, X., Gelbert, L.M., Nisenbaum, L.K. Neurobiol. Dis. (2004) [Pubmed]
  31. Effect of the selective 5-HT3 receptor antagonists ICS 205-930 and MDL 72222 on 5-HTP-induced head shaking and behavioral symptoms induced by 5-methoxy-N,N,dimethyltryptamine in rats: comparison with some other 5-HT receptor antagonists. Shearman, G.T., Tolcsvai, L. Psychopharmacology (Berl.) (1987) [Pubmed]
  32. Deficient response inhibition as a cognitive endophenotype of ADHD. Slaats-Willemse, D., Swaab-Barneveld, H., de Sonneville, L., van der Meulen, E., Buitelaar, J. Journal of the American Academy of Child and Adolescent Psychiatry. (2003) [Pubmed]
  33. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. Aman, M.G., Gharabawi, G.M. The Journal of clinical psychiatry. (2004) [Pubmed]
  34. Haloperidol versus thioridazine in the treatment of behavioral symptoms in senile dementia of the Alzheimer's type: preliminary findings. Steele, C., Lucas, M.J., Tune, L. The Journal of clinical psychiatry. (1986) [Pubmed]
  35. Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Lopez, O.L., Wisniewski, S.R., Becker, J.T., Boller, F., DeKosky, S.T. Arch. Neurol. (1999) [Pubmed]
  36. Cerebral ischemia decreases the behavioral effects and mortality rate elicited by activation of NMDA receptors in mice. Himori, N., Moreau, J.L., Martin, J.R. Neuropharmacology (1991) [Pubmed]
  37. Decreased signs of nicotine withdrawal in mice null for the beta4 nicotinic acetylcholine receptor subunit. Salas, R., Pieri, F., De Biasi, M. J. Neurosci. (2004) [Pubmed]
WikiGenes - Universities